News

Evosep unveils new instrumentation and partnership at ASMS 2025

Evosep Eno The new Evosep Eno from Evosep will set the stage for next generation LC-MS based proteomics BALTIMORE, Md.,…

7 months ago

Solera Health Unveils Enhanced AI Governance Framework for Responsible and Transparent Use of Artificial Intelligence in Digital Health

Framework Sets an Industry Benchmark for Client Trust and Ethical AI Use to Ensure Patient Safety and AccountabilityPHOENIX, June 02,…

7 months ago

Myriad Genetics Shares New Clinical Data Demonstrating Sensitivity of Precise MRD Across Multiple Cancer Types

MONSTAR-SCREEN-3 study showed 100% detection of circulating tumor DNA (ctDNA) at baseline timepoint, and 60% of patients testing positive one…

7 months ago

Liberation Labs is Now Liberation Bioindustries

New name, new brand better reflects the company’s position as a global, commercial-scale biomanufacturer Liberation Labs Rebrands: Now Liberation Bioindustries…

7 months ago

PathAI and Northwestern Medicine Announce Strategic Collaboration to Deploy the AISight® Digital Pathology Platform and Co-Develop New AI Diagnostics

Collaboration includes use of PathAI’s AISight®¹ digital pathology image management system at Northwestern Medicine and joint efforts in research, clinical…

7 months ago

New Independent Review Paper Strengthens Therapeutic Rationale for Artelo’s FABP Inhibitor Program in Anxiety and Depression

SOLANA BEACH, Calif., June 02, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on…

7 months ago

Actuate Therapeutics Shares Highlights from KOL Event on Positive Topline Elraglusib Phase 2 Data in First-Line Treatment of Metastatic Pancreatic Cancer

- Expert Insights on Clinical Relevance and Scientific Rationale- The replay of the event is available on the Investor Relations…

7 months ago

TerrAscend Announces Chief Financial Officer Transition Plan

TORONTO, June 02, 2025 (GLOBE NEWSWIRE) -- TerrAscend Corp. (“TerrAscend” or the “Company”) (TSX: TSND, OTCQX: TSNDF), a leading North…

7 months ago

Xilio Therapeutics Announces Pricing of $50.0 Million Public Offering

WALTHAM, Mass., June 02, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing…

7 months ago